Medpace (MEDP) insider exercises 18,230 options, sells 15,230

Medpace Holdings (MEDP): Form 4 insider transaction — On 10/27/2025, General Counsel & Corp. Secy.

Rhea-AI Filing Summary

Medpace Holdings (MEDP): Form 4 insider transaction — On 10/27/2025, General Counsel & Corp. Secy. Stephen P. Ewald exercised 18,230 employee stock options at $166.73 and sold 15,230 shares of common stock at a weighted average price of $598.85 (transactions ranged from $596.25 to $602.955). Following these transactions, he beneficially owned 13,343 shares directly. The option was reported to have vested in full on October 27, 2025, and the derivative position was reduced to 0; the option carried an expiration date of 10/27/2026.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider EWALD STEPHEN P

Role General Counsel & Corp. Secy.

Sold 15,230 shs ($9.12M)

Approx. gross sale proceeds $9.12M

Approx. exercise cost $3.04M

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy)	18,230	$0.00	$0.00
Exercise	Common Stock	18,230	$166.73	$3.04M
Sale	Common Stock	15,230	$598.85	$9.12M

Holdings After Transaction: Employee Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 13,343 shares (Direct)

Footnotes (2)

1. F1. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $596.25 to $602.955. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
2. F2. The option vested in full on October 27, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MEDP insider Stephen P. Ewald report on Form 4?

He exercised 18,230 options at $166.73 and sold 15,230 common shares at a $598.85 weighted average on 10/27/2025.

How many MEDP shares does the insider own after the transactions?

He beneficially owns 13,343 shares directly after the reported transactions.

What was the price range for the MEDP share sales?

Sales occurred in multiple trades ranging from $596.25 to $602.955.

What were the terms of the exercised options for MEDP?

Employee stock options to buy 18,230 shares at $166.73 vested in full on 10/27/2025 and had an expiration date of 10/27/2026.

What is the insider’s role at Medpace (MEDP)?

Stephen P. Ewald is General Counsel & Corporate Secretary.

How many derivative securities remain after the exercise?

The number of derivative securities reported as owned after the transactions is 0.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/29/2025 - 04:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EWALD STEPHEN P

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS,INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel & Corp. Secy.

3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/27/2025		M		18,230	A	$166.73	28,573	D
Common Stock	10/27/2025		S		15,230	D	$598.85(1)	13,343	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$166.73	10/27/2025		M			18,230	(2)	10/27/2026	Common Stock	18,230	$0	0	D

Explanation of Responses:

1. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $596.25 to $602.955. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

2. The option vested in full on October 27, 2025.

Remarks:

	/s/ Stephen P. Ewald	10/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.